ImCheck Therapeutics Alternatives & Competitors
12 companies similar to ImCheck Therapeutics — Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the c...
Companies similar to ImCheck Therapeutics
Alloplex Biotherapeutics Inc
A robust cellular therapeutic platform for treating cancer.
Boston, United States
FineImmu
Creating future health with advanced cell therapy drugs and precision immunodiagnostic pro...
NextPoint Therapeutics, Inc.
Launching a new world of precision therapeutics through its leading scientific work on th...
ImmunOs Therapeutics AG
Novel human immunomodulatory proteins for cancer and autoimmune diseases with a specific r...
Schlieren, Switzerland
Track all ImCheck Therapeutics competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
AltruBio Inc.
Novel Therapeutics for Immunological Diseases
San Francisco, United Sta...
Georgiamune Inc.
Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fi...
Gaithersburg, United Stat...
Apexigen
Creating Transformative Immunotherapies for Patients with Cancer
San Carlos, United States
Quentis Therapeutics
Developing innovative immuno-therapeutics to combat ER stress and empower the immune syste...
Glycyx
Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance...
San Francisco, United Sta...
Oncofactor Corporation
A Seattle-based innovator in cancer treatments, disrupting tumor-immune system signaling p...
Biond Biologics Ltd
Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics f...
Israel
Gritstone bio
A lean biotech company aiming to develop revolutionary immune-based treatment for various...
Emeryville, United States
About ImCheck Therapeutics
ImCheck Therapeutics, with the slogan "Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic," is focused on designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. Their lead clinical-stage program ICT0...
development of immunotherapeutic antibodies, immune system modulation research, clinical research in AML patients
patients with cancer, patients with infectious diseases, patients with autoimmune diseases
Immunotherapy, Oncology, Antibody Therapeutics, Cancer Treatment, Immune Checkpoint Inhibitors, Autoimmune Diseases, Immunomodulators, Biopharmaceuticals, Drug Development, Precision Medicine
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches ImCheck Therapeutics and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at ImCheck Therapeutics on 11 Jun 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
